|

Fexofenadine in Patients With Active Rheumatoid Arthritis

RECRUITINGPhase 1/2Sponsored by October 6 University
Actively Recruiting
PhasePhase 1/2
SponsorOctober 6 University
Started2022-06-01
Est. completion2025-12
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05264025

Summary

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria

* Moderate to severe RA (disease activity score-28 joints: DAS-28 \> 3.2) were recruited.
* Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
* Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.

Exclusion Criteria:

* History of biological DMARDS.
* History/presence of acute heart disease, liver and kidney diseases, COPD
* Intolerance or allergy to fexofenadine or methotrexate
* Alcohol abuse
* Any changes in using medication (changing the dosage or type of medicines
* Receive hormone replacement therapy, warfarin, and other anticoagulants

Conditions2

ArthritisRheumatoid Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.